期刊文献+

2003年~2005年我院血管紧张素转换酶抑制剂用药情况分析 被引量:2

Utilization of Angiotensin Converting Enzyme Inhibitors(ACEIs) in Our Hospital During the Period 2003~2005
下载PDF
导出
摘要 目的:分析我院血管紧张素转换酶抑制剂的用药情况及趋势。方法:用金额排序法对我院2003年-2005年血管紧张素转换酶抑制剂的用药数据进行统计分析。结果:ACE抑制剂的消耗金额逐年上升,卡托普利和贝那普利的消耗金额与用药频度居前2位。结论:合资血管紧张素转换酶抑制剂在我院的使用中占主要地位,长效血管紧张素转换酶抑制剂有良好的前景。 OBJECTIVE:To analyze the utilization and its tendency of angiotensin converting enzyme inhibitors (ACEIs) in our hospital. METHODS: The utilization data of ACEI in our hospital during 2003 -2005 were analyzed statistically according the order of consumption sum of money. RESULTS : The consumption sum of money of ACEIs increased year by year, leading the first two places in terms of consumption sum of money and DDDs were Captopril and Benazepril. CONCLUSION: The ACEI made in joint ventures occupied the most important place in our hospital, and the long-acting ACEI shows a promising prospect.
作者 陈锦华
出处 《中国医院用药评价与分析》 2007年第3期202-204,共3页 Evaluation and Analysis of Drug-use in Hospitals of China
关键词 血管紧张素转换酶抑制剂 用药分析 Angiotensin converting enzyme inhibitor (ACEI) Drug utilization analysis
  • 相关文献

参考文献4

二级参考文献41

  • 1傅蕾,李秀芝.长期服用福辛普利对左室舒张功能的影响[J].海南医学,2004,15(10):60-60. 被引量:1
  • 2杨进刚,胡大一.血管紧张素转化酶抑制剂与肾功能的临床评价[J].中国医院用药评价与分析,2004,4(4):198-201. 被引量:13
  • 3刘力生,龚兰生,王文,降压治疗预防卒中再发研究协作组.降压治疗对中国脑血管病患者脑卒中再发预防的多中心随机双盲对照临床研究[J].中华心血管病杂志,2005,33(7):613-617. 被引量:49
  • 4张华吉 李环.Zeneca公司的赖诺普利成为处方量最大的ACEI.国外药迅,1999,4:24-24.
  • 5张健 华琦.高血压个体化治疗[M].北京:人民卫生出版社,2001.196-231.
  • 6JNC-7 Express. The seventh report of the joint national committee on prevention detection evaluation and treatment of high blood pressure, U.S. National Institute of Health-National Heart, Lung, and Blood Institute, NIH Publication No. 03--52;33, May 200;3.
  • 7Claude Lenfant, Aram V Chobanian, Danicl W Jones, et al.Resetting the hypertension sails. Hypertension 2003; 41 :1178--1179.
  • 8Ramachandran S, Vasan MD, Alexa Beiser, et al. Residual lifetime risk for developing hypertension in middle-aged women and men. JAMA 2002 ; 287:1003--1010.
  • 9Manning J,Vehaskari VM.Postnatal modulation of prenatally programmed hypertension by dietary Na and ACE inhibition[J].Am J Physiol Regul Integr Comp Physiol,2005,288(1):R80.
  • 10Schofield RS,Kline SE,Schmalfuss CM,et al.Early outcomes of a care coordination-enhanced telehome care program for elderly veterans with chronic heart failure[J].Telemed J E Health,2005,11 (1):20.

共引文献39

同被引文献12

  • 1张言.血管紧张素转换酶抑制剂的临床应用分析[J].中西医结合心脑血管病杂志,2005,3(2):180-181. 被引量:14
  • 2王莉,陆融,王犁明,赵琳,傅正,王松,李会强,杨海贤,章明放,金孟珏,姚智.酪丝亮肽对人肝癌BEL-7402裸鼠移植瘤的抑制作用[J].中国新药与临床杂志,2005,24(11):857-861. 被引量:6
  • 3赵超尘,李君,王平,王学浩.酪丝亮肽治疗手术不能切除的原发性肝癌临床疗效观察[J].中国现代医学杂志,2007,17(3):357-359. 被引量:8
  • 4Bolette Hartmann, Mette B Harr, Palle B, et al. In vivo and in vitro degradation of glucagon-like peptide-2 in humans [J]. The Journal of Clinical Endocrinology & Metabolism, 85(8) : 2884.
  • 5Y Vanneste, A Michel, R Dimaline,et al. Hydrolysis of alpha human atrial natriuretic peptide in vitro by human kidney membranes and purified endopeptidase-24. 11. Evidence for a novel cleavage site[J]. Biochem J, 1988,254(2) : 531.
  • 6Harald John, Stefanie Schulz , Wolf-Georg Forssmann, et al. Comparative in vitro degradation of the human hemorphin LVV-H7 in mammalian plasma analysed by capillary zone eleetrophoresis and mass spectrometry[J]. Biopharmaceutics & Drug Disposition, 2006,28(2) : 73.
  • 7Fujioka Y, Satake S, Uehara T, etal. In vitro system to estimate renal brush border enzyme-mediated cleavage of Peptide linkages for designing radiotabeled antibody fragments of low renal radioactivity levels[J]. Bioconjug Chem, 2005,16 (6):1610.
  • 8Naidu A, Quon D Cordell B, et al. Beta-Amyloid peptide produced in vitro is degraded by proteinases released by cultured cells[J]. The Journal of Biological Chemistry, 1995, 270(3):1369.
  • 9Harald John, Kham Dieu Huynh, Christiane Hedtmann, et al. In vitro degradation of the antimierobial human peptide HEM-c130-146 in plasma analyzed by a validated quantitative LC-MS/MS procedure[J]. Analytical Biochemistry, 2005, 341(173 - 186) : 173.
  • 10中国高血压防治指南起草委员会.中国高血压防治指南[M].2005修订版.北京:人民卫生出版社,2005:60-61.

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部